<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01760772</url>
  </required_header>
  <id_info>
    <org_study_id>12-09-20-01</org_study_id>
    <nct_id>NCT01760772</nct_id>
  </id_info>
  <brief_title>Effect of GLP-1 on Postprandial Lipid Metabolism</brief_title>
  <official_title>The Role of GLP-1 in Lipid Metabolism in Healthy Subjects and in Subjects After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Dalessio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals with obesity have an increased risk for heart disease and diabetes. There are&#xD;
      current drugs on the market that target the hormone, Glucagon like peptide-1 (GLP-1) to treat&#xD;
      diabetes. The investigators want to determine if targeting this hormone will also help people&#xD;
      with high cholesterol and triglycerides. In this study, the investigators are looking at the&#xD;
      role of GLP-1 in healthy subjects and subjects that have had bariatric surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major consequences of the global pandemic of obesity include cardiovascular disease, type 2&#xD;
      diabetes and dyslipidemia. The dyslipidemia of obesity commonly consists of fasting&#xD;
      hypertriglyceridemia with increased plasma very low-density lipoprotein (VLDL), reduced&#xD;
      high-density lipoprotein (HDL) and the presence of small, dense low-density lipoprotein&#xD;
      (LDL). However, more recently, increased secretion of intestinally derived lipoproteins (LPs)&#xD;
      has been recognized as contributing to this dyslipidemic profile and postprandial lipemia has&#xD;
      been linked to adverse health outcomes. Glucagon-like peptide-1 (GLP-1), a hormone secreted&#xD;
      during meal absorption that plays a key role in the control of plasma glucose has been&#xD;
      implicated as a candidate hormone for regulating intestinal lipid metabolism. Studies in&#xD;
      rodents demonstrate that treatment with the GLP-1R agonist; exendin-4 (Ex-4) reduced&#xD;
      postprandial chylomicron (CM) production and CM-associated cholesterol and triglyceride (TG).&#xD;
      Similar results were found in Type 2 diabetes (T2D) subjects treated with Ex-4; in these&#xD;
      reports there was a reduction in both intestinally derived LP production and total plasma TG.&#xD;
      The objective of this study is to determine whether GLP-1 is involved in the physiologic&#xD;
      regulation of postprandial lipid metabolism in healthy women, and to test the hypothesis that&#xD;
      the improved lipid parameters found in overweight women who have had bariatric surgery are&#xD;
      mediated by GLP-1. The specific aims for this project will 1) determine if either&#xD;
      pharmacologic treatment with GLP-1 and/or antagonism of endogenous GLP-1 activity improves&#xD;
      postprandial lipid metabolism in healthy subjects and 2) determine the role of elevated&#xD;
      postprandial GLP-1 levels on lipid metabolism in obese subjects who have had a sleeve&#xD;
      gastrectomy. The investigators will use infusions of synthetic GLP-1 with the native hormone&#xD;
      to confirm the lipid-lowering results that have been published using pharmacologic GLP-1&#xD;
      receptor (GLP-1R) agonists. The investigators will also use the GLP-1R antagonist&#xD;
      exendin-(9-39) to determine the role of endogenous GLP-1 on lipemia after a test meal. A&#xD;
      demonstration that this is a physiologic action would expand the current understanding of&#xD;
      lipid metabolism, provide new insight into the effects of bariatric surgery, and allow the&#xD;
      design of more refined, mechanistic studies of this process. In addition, the potential for&#xD;
      GLP-1R signaling to promote lipid metabolism has direct translational importance in that&#xD;
      therapies already exist that could capitalize on this mechanism. Understanding the role of&#xD;
      GLP-1R regulation of lipid absorption and clearance could lead to more appropriate targeting&#xD;
      of GLP-1 based drugs to specific diabetic patients, i.e. ones with problematic dyslipidemia&#xD;
      and higher risk for cardiovascular disease. Moreover, understanding the effects of GLP-1 on&#xD;
      plasma lipids could eventually lead to new approaches for treating nondiabetic dyslipidemic&#xD;
      persons.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial Lipids Levels and Apolipoprotein B (ApoB) Levels in plasma</measure>
    <time_frame>2 years</time_frame>
    <description>Total and lipoprotein-associated triglyceride and cholesterol levels in baseline and postprandial plasma.&#xD;
Total apolipoprotein B48 (ApoB48) and apolipoprotein B100 (ApoB100) levels in baseline and postprandial plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin and glucagon</measure>
    <time_frame>2 years</time_frame>
    <description>Plasma insulin and glucagon in the fasting and postprandial periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma free fatty acid (FFA) and glucose levels</measure>
    <time_frame>2 years</time_frame>
    <description>Plasma FFA and glucose levels during the fasting and postprandial state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma d-xylose and acetaminophen levels</measure>
    <time_frame>2 years</time_frame>
    <description>Plasma d-xylose and acetaminophen levels as indices of gastric emptying</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin-9 (Ex-9)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bolus of Ex-9 (7,500 pmol/kg) followed by a continuous infusion at 750 pmol/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLP-1 infusion at 0.3 pmol/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin-9</intervention_name>
    <description>Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min</description>
    <arm_group_label>Exendin-9 (Ex-9)</arm_group_label>
    <other_name>Synthetic exendin (9-39) injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>Constant infusion of GLP-1 at 0.3 pmol/kg/min</description>
    <arm_group_label>GLP-1</arm_group_label>
    <other_name>7-36 amide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>Constant infusion</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aim 1: Healthy, normolipemic men and postmenopausal women; aged 40-60 years; BMI&#xD;
             between 25-35&#xD;
&#xD;
          -  Aim 2: Men and postmenopausal women after successful vertical sleeve gastrectomy (VSG)&#xD;
             surgery and age- and weight-matched non-surgical control men and postmenopausal women;&#xD;
             ages between 40-6- years; BMI between 28-35; steady weight for at least 3 months prior&#xD;
             to study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion Criteria for Aim 1:&#xD;
&#xD;
          -  History or clinical evidence of impaired fasting glucose or diabetes mellitus,&#xD;
             myocardial infarction or symptoms of congestive heart failure, history or active liver&#xD;
             or renal disease, calculated glomerular filtration rate &lt; 60 mL/min).&#xD;
&#xD;
          -  History of extreme dyslipidemia (i.e. familial hypercholesterolemia) or Cardiovascular&#xD;
             disease (CVD).&#xD;
&#xD;
          -  Fasting plasma total cholesterol &gt; 200 mg/dL and fasting plasma TGs &gt; 150 mg/dL.&#xD;
&#xD;
          -  Surgery within 6 months.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Anemia defined as hematocrit &lt; 33%.&#xD;
&#xD;
          -  History of cancer or anorexia nervosa or GI disorders.&#xD;
&#xD;
          -  Use of medications that alter insulin sensitivity (i.e. niacin, glucocorticoids,&#xD;
             metformin) or lipid metabolism (i.e. statin, niacin, fibrate, ezetimibe).&#xD;
&#xD;
          -  Plasma HbA1c &gt; 6.0.&#xD;
&#xD;
          -  Fasting glucose &gt; 110 mg/dL&#xD;
&#xD;
          -  Electrocardiogram (ECG) abnormalities: evidence of ischemia or arrhythmia.&#xD;
&#xD;
        Exclusion Criteria for Aim 2:&#xD;
&#xD;
          -  History of CVD.&#xD;
&#xD;
          -  Fasting plasma total cholesterol &gt; 250 mg/dL and fasting plasma TGs &gt; 300 mg/dL.&#xD;
&#xD;
          -  Surgical intervention within 6 months.&#xD;
&#xD;
          -  Anemia defined as hematocrit &lt; 33%.&#xD;
&#xD;
          -  History of cancer or anorexia nervosa or other major GI disease or surgery.&#xD;
&#xD;
          -  Use of medications that alter insulin sensitivity (i.e. niacin, glucocorticoids,&#xD;
             metformin) or lipid metabolism (i.e. statin, ezetimibe).&#xD;
&#xD;
          -  HbA1c &gt; 6.0.&#xD;
&#xD;
          -  Fasting glucose &gt; 110 mg/dL&#xD;
&#xD;
          -  Electrocardiogram (ECG) abnormalities: evidence of ischemia or arrhythmia.&#xD;
&#xD;
          -  Significant renal, hepatic or pulmonary disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle R Adams, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David D'Alessio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle R Adams, PhD</last_name>
    <phone>513-558-6920</phone>
    <email>michelle.adams@uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David D'Alessio, MD</last_name>
    <phone>513-558-6689</phone>
    <email>DALESSD@UCMAIL.UC.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Veteran's Affairs Clinical Research Unit</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michelle R Adams, PhD</last_name>
      <phone>513-558-6920</phone>
      <email>michelle.adams@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Michelle R Adams, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David D'Alessio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>November 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <last_update_submitted>January 2, 2013</last_update_submitted>
  <last_update_submitted_qc>January 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>David Dalessio</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>heart disease</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Exendin-9</keyword>
  <keyword>postprandial lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

